Preclinical News and Research

RSS
Adaptimmune announces new board appointments as clinical programmes get underway

Adaptimmune announces new board appointments as clinical programmes get underway

Novel bipartite gene therapy for retinitis pigmentosa

Novel bipartite gene therapy for retinitis pigmentosa

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Circadian subsidiary submits IND application to FDA to initiate VGX-100 study against cancer

Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J.

Roche inaugurates new clinical supply manufacturing facility in Nutley, N.J.

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Enrollment begins in Boston Scientific's vagal nerve stimulation trial for heart failure

Enrollment begins in Boston Scientific's vagal nerve stimulation trial for heart failure

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials

DSMB authorizes ACT to proceed with next set of patients in stem cell clinical trials

Prototype drug shows promise against chronic lymphocytic leukemia

Prototype drug shows promise against chronic lymphocytic leukemia

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

SanBio initiates SB623 Phase 1/2a clinical trial in ischemic stroke

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus

MicroDose initiates MDT-637 Phase 1 trial in respiratory syncytial virus

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Zoledronic acid may benefit post-menopausal women with breast cancer

Zoledronic acid may benefit post-menopausal women with breast cancer

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Laurantis Pharma's Lymfactin rebuilds lymphatic vessels in pre-clinical animal models

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

YM BioSciences total revenue decreases to $1.5 million for fiscal 2011

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.